RecruitingPhase 1NCT07029399
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NiKang Therapeutics, Inc.
- Intervention
- NKT5097 CDK2/CDK4 dual degrader(drug)
- Enrollment
- 205 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (14)
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- SCRI Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
- Washington University, St Louis, Missouri, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio, Texas, United States
- South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City, Utah, United States
- NEXT Virginia, Fairfax, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07029399 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.